iShares Biotechnology ETF
891 hedge funds and large institutions have $5.39B invested in iShares Biotechnology ETF in 2022 Q1 according to their latest regulatory filings, with 81 funds opening new positions, 258 increasing their positions, 328 reducing their positions, and 132 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
891
Holders Change
-64
Holders Change %
-6.7%
% of All Funds
14.1%
Holding in Top 10
13
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+30%
% of All Funds
0.21%
New
81
Increased
258
Reduced
328
Closed
132
Calls
$285M
Puts
$254M
Net Calls
+$31.5M
Net Calls Change
-$12.1M
Top Buyers
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$86.4M |
| 2 |
Jane Street
New York
|
+$63.7M |
| 3 |
Goldman Sachs
New York
|
+$51.5M |
| 4 |
Bessemer Group
Woodbridge,
New Jersey
|
+$51.4M |
| 5 |
Citigroup
New York
|
+$49.1M |
Top Sellers
| 1 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$107M |
| 2 |
Morgan Stanley
New York
|
-$94.4M |
| 3 |
CI Investments Inc
Toronto,
Ontario, Canada
|
-$73.8M |
| 4 |
Two Sigma Advisers
New York
|
-$38M |
| 5 |
Two Sigma Investments
New York
|
-$34.9M |
